FDA Confirms Nose Ointment Wasn't Pulled for Being Terrible
Published Date: 12/12/2025
Notice
Summary
The FDA has decided that BACTROBAN (mupirocin) nasal ointment, 2%, wasn’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, as long as they meet all the rules. Patients and pharmacies could see more affordable options soon, with no safety worries holding things back.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generic Makers May Seek Approval
If you make generic drugs, you can now apply to sell a generic version of BACTROBAN (mupirocin) nasal ointment, 2%. The FDA determined this product was not withdrawn for reasons of safety or effectiveness, so abbreviated new drug applications (ANDAs) referencing this listed drug may be approved if they meet all other legal and regulatory requirements.
More Affordable Options Possible
You (patients and pharmacies) could see more affordable options for BACTROBAN (mupirocin) nasal ointment, 2%, because the FDA found it was not withdrawn for safety or effectiveness and said generic versions may be approved. This change makes it possible that lower-cost generic versions could enter the market.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in